Obesity and prostate cancer detection: insights from three national surveys.
BACKGROUND
Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys.


METHODS
We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n=845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n=2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n=4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories.


RESULTS
Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P=.24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P=.01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P=.05).


CONCLUSIONS
Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.
Parekh
Niyati
N
Department of Nutrition, New York University, New York, NY, USA.
Lin
Yong
Y
Dipaola
Robert S
RS
Marcella
Stephen
S
Lu-Yao
Grace
G
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001706:Biopsy; D015992:Body Mass Index; D018450:Disease Progression; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D009749:Nutrition Surveys; D009765:Obesity / Q000150:complications* / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
Int J Obes (Lond). 2007 Apr;31(4):685-91
16969359
J Urol. 2006 Feb;175(2):500-4; discussion 504
16406980
J Natl Cancer Inst. 1997 Mar 5;89(5):385-9
9060961
Urology. 2006 Aug;68(2):342-7
16904449
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):808-15
19258479
Epidemiol Rev. 2007;29:88-97
17478439
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):70-6
17179487
JAMA. 2006 Apr 5;295(13):1549-55
16595758
Urology. 2001 Nov;58(5):723-8
11711349
J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4
12928350
Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):557-63
9264267
Can J Urol. 2008 Dec;15(6):4363-74
19046489
BJU Int. 2009 Nov;104(10):1457-61
19522868
N Engl J Med. 2003 Apr 24;348(17):1625-38
12711737
J Natl Cancer Inst. 2006 Apr 19;98(8):529-34
16622122
Vital Health Stat 2. 1992 Sep;(113):1-35
1413563
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Int J Cancer. 2007 Oct 1;121(7):1571-8
17450530
Can J Urol. 2006 Apr;13 Suppl 2:11-7
16672123
N Engl J Med. 2004 May 27;350(22):2239-46
15163773
Cancer. 2007 Feb 15;109(4):675-84
17211863
Eur J Endocrinol. 2006 Sep;155(3):443-52
16914599
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):345-53
11319175
Arch Androl. 2006 Sep-Oct;52(5):355-61
16873135
BMJ. 2002 Oct 5;325(7367):740
12364300
Int J Urol. 1998 Mar;5(2):134-7
9559838
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1417-21
14693731
J Clin Oncol. 2004 Feb 1;22(3):446-53
14691122
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2343; author reply 2343-4
19661096